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To determine whether exercise-induced increases In tissue plasmi .
nogen activator (t-PA) were related to plasma epinephrine can .
centration during exercise, 14 healthy men (aged 24 to 62 years)
were studied during epinephrine infusions (10, 25 and 50 ng/kg
per min) and graded supine bicycle exercise, beginning at 33 W
end Increasing in 33-W increments until exhaustion . Plasma
epinephrine, active and total t-PA, active plasminogen activator
inhibitor type 1 (PAI-1) and t-PA/PAI-l complex concentrations
wee measured at each exercise and infusion level .
During epinephrine Infusion, active and total I-PA levels in .
creased linearly with the plasma epinephrine concentration (respec-
tive stapes [x SEMI of 0.062 ± 0.003 and 0.076 m 0.003 pirating
emnephrtue). During exercise, t-PA levels did not increase until
plasma epinephrine levels increased, after which both active and
total t-PA levels again increased linearly with the plasma epineph .
rine concentration, but at twice the rate observed with epineph.
Vigorous exercise produces an increase in circulating tissue
plasminogen activator (t-PA) (1,2) . One possible mechanism
to explain the increase in t-PA during exercise is release of
factors such as epinephrine that increase during exercise and
stimulate t-PA secretion . For any factor proposed to stimu-
late t-PA release during exercise, the dose-response and time
course oft-PA release should be similar for plasma levels of
the factor attained during exercise and during infusion of the
factor. Although prior work (3) has suggested that increased
epinephrine during exercise may be a release stimulus for
t-PA, no study to date has evaluated t-PA release during
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rive infusion (0.131 ± 0 .005 and 0.147 ± 0.005 paroling, respec-
lively).
The (-PA level in blood was directly proportional to the plasma
epinephrine concentration during both exercise and epinephrine
infusion, suggesting that epinephrine release during exercise stim-
Wates t-PA secretion. In these healthy subjects, active plasmino-
gee activator inhibitor type 1 and t-PAIPAII complex levels were
low (41 ± 11 and 21 ± 5 pmot/liter, respectively) and did not
change significantly during exercise or epinephrine infusion.
It is concluded that approximately 50% of the Increase in t-PA
during exercise is due to stimulated release oft-PA by epineph-
rine. Other factors, inch as reduced hepatic clearance during
exercise, must account for the remaining 50% of the increase In
t-PA,
fJ Am Coll Cordiol 1"2
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exercise and epinephrine infusion in the same subjects . Most
studies (1-12) have not directly compared epinephrine levels
and t-PA release during exercise, but have evaluated only
exercise or epinephrine infusion. One study (5) reported no
relation between epinephrine and fibrinolysis during exercise
but used exercise protocols that produced only minor
changes in epinephrine before the patient reached exhaus-
tion, lacked epinephrine infusion data, measured only global
fibrinolytic activity rather than specific components and
used less accurate assays for catecholamines .
The purpose of our study was to determine the relation
between plasma epinephrine levels and fibrinolytic activity
during exercise and epinephrine infusion . Three factors
separate our study from prior investigations . First, the
response to epinephrine infusion and graded exercise 'vas
evaluated in the same subjects. Second, fibrinolysis was
evaluated at three infusion rates of epinephrine and up to
nine levels of exercise, This allowed a comparison of the rate
of change (slope) of t-PA versus plasma epinephrine concen
.
notion during infusion and exercise in each subject
. Third, at
each epinephrine infusion rate and exercise level, a complete
evaluation of the fibrinolytic system was performed, includ-
ing measurement of active and total t-PA, active plasmino-
0735-10971921x5 .00
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gen activator inhibitor I (PAI-I), t-PA/PAI-I complex and
plasma epinephrine . During both epinephrine infusion and
exercise, the concentration oft-PA in the blood was directly
proportional to the plasma epinephrine level, suggesting that
increased epinephrine levels during exercise stimulate t-PA
release.
Methods
Study subjects. Studies in human subjects were carried
out according to the principles of the Declaration of Hel-
sinki . Written, informed consent was obtained from all
participants and the study was approved b, the University
of Washington Human Subjects Review Committee . The
study group consisted of 14 healthy men aged 24 to 62 years
(mean 30 ± 10) . Entry criteria included no medication
use, no history of angina, myocardial infarction, stroke,
chronic pulmonary disease, diabetes or hypertension and no
exercise-limiting orthopedic impairment . Entry laboratory
requirements included a normal hernatocrit, fasting blood
glucose and total cholesterol levels and normal findings on a
rest and exercise electrocardiogram. maximal exercise stress
test and M-mode and two-dimensional echocardiogram .
Exercise and epinephrine infusion protocol . All studies
were performed during the late morning and early afternoon .
Two intravenous lines were placed in the right arm . Epi-
nephrine was infused into the antecubital vein and blood
samples were obtained from a hand or wrist vein. The hand
was warmed before the venous sample was obtained . a s
previously described (13)
.
For the epinephrine infusion
study, baseline samples were taken after 30 min of supine
rest just before the start of the infusion . Samples were then
obtained after infusion of 10, 25 and 50 ng/kg per min of
epinephrine for 10 min each. For the exercise study, baseline
samples were obtained after another 30-min supine rest
period just before the start of exercise
. Samples were taken
at the end of each 3-min supine bicycle exercise stage, which
began at 33 W and increased by 33-W increments until
exhaustion
.
Blood sampling and sample preparation . Blood for fibrin-
olytic studies was anticoagulated by addition of 1 .8 ml of
whole blood to 0.2 ml of 130 mmoljliter sodium citrate. To
stabilize t-PA activity, 0
.5 ml of citrate anticoagulated whale
blood was mixed with 0.25 ml of 0.5 M sodium acetate, pH
4 .2, within I min after the sample was drawn
(14) . All
samples were centrifuged for 10 min at 1,000 g at room
temperature . Plasma and acidified plasma were then re-
moved and frozen at -60°C until analyzed .
For carecholamine analysis, 2
.5 ml of whole blood was
added to a prechilled tube containing 50 (al of 0.15 mol/liter
sodium chloride, 90 g/liter ethylene glycol tetraacetic acid
(EGTA) and 60 gfliter reduced glutathione . Catecholamine
samples were centrifuged at 4°C for 15 min at 900 g, the
plasma removed and recentrifuged as before and the super-
natant removed and stored in tightly sealed plastic tubes at
-80°C .
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Materials . Human fibrinogen, cyanogen bromide and
Triton-X-100 were obtained from Sigma Chemical Co . Cy-
anogen bromide-cleaved human fibrinogen fragments were
prepared as previously described (14) . Chromogenic sub-
strate D-vatyl-phenylalanyl-lysyl-p-vitro-analide (S-2390)
was obtained from KabiVitrum. Human glu-plasminogen,
one-chain melanoma-derived t-PA (512,000IUlmg) and goat
antihuman t-PA and its peroxidase conjugate were obtained
from American Diagnostica . Microliter plates precoated
with monoclonal antihuman t-PA and monoclonal antihuman
PAI-I peroxidase conjugate were provided by American
Bioproducts (15) . All other materials were reagent or ana-
lytic grade .
Activity assay for I-PA. t-PA activity was measured in
acidified plasma by an amidolylic method, as previously
described (14) . Briefly, the acidified plasma sample was
incubated with a solution containing human plasminogen,
cyanogen bromide-cleaved human fibrinogen fragments and
the plasmin-sensitive chromogenic substrate D-valyl-
phenylalanyl-lysyl-p-nitroanilide in a Tris buffer (pH 8.2) at
37°C for 90 to 120 min. The change in absorbance at 405 run
was directly proportional to t-PA activity in the sample .
Results were initially expressed in international units (11 .1) by
comparison with the second international t-PA activity stan-
dard (86/670) from the National Institute for Biologic Stan-
dards and Control (16). Results of t-PA activity were con-
verted into molar concentrations of active t-PA by using a
specific molar activity of 4.48 x 1013 lU/mol (17)
.
The
intraassay and inteaassay standard deviations for active t-PA
were 21 ± I and 21 ± 2 pmol/liter, respectively (14) .
Total t-PA antigen assay . Total t-PA antigen was deter-
mined in citrated plasma by using an enzyme-linked im-
muno: srbent assay (ELISA), essentially as described by
R6nby ct al . (18,19). Briefly, ,nicroliter plates coated with a
polyclonal antihuman t-PA antibody were incubated with
human plasma and unbound proteins washed off and bound
t-PA was identified with a polyclonal antihuman t-PA per-
oxidase conjugate. One-chain t-PA diluted in normal plasma
was used to construct the standard curve. Rsnby et al . (19)
showed that this assay has a recovery of 100% for free t-PA
and t-PA complexed to active plasminogen activator inhibi-
tor type I in plasma
. The intraassay and interassay standard
deviations for total t-PA were 122 ± 4 and 89 .k 8 pmollliter,
respectively (17) .
Active plasminogen activator inhibitor type I and t-PAl
PAI-1 complex assays. The plasminogen activator inhibitor
type I (PAI-1) activity was determined by adding active
one-chain t-PA to an aliquot of plasma (dual concentration
25 IU/ml), followed by incubation for 15 min at 37°C . The
concentration of t-PAIPAI-I complex was measured in
plasma before and after the addition of excess t-PA with a
modified ELISA method, as previously described (15,17,20).
Briefly, microliter plates coated with a monoclonal antihu-
man t-PA antibody were incubated with human plasma,
unbound proteins were washed off and bound t-PA/PAI-I
complex was identified with a monoclonal antihuman ptas-
1414
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minogen activator inhibitor type I peroxidase conjugate
.
Partially purified t-PA/PAl-I complex was used to construct
the standard curve
(17). The concentration of active plas-
minogen activator inhibitor type I was equal to the differ-
ence in t-PA/PAI-I complex before versus after the addition
of t-PA
. Active plasminogen activator inhibitor type I
(PAI-I) levels (in ng/mi) were converted to molar concentra-
lions assuming a molecular weight of 52
.(X10 for plasminogen
activator inhibitor type 1 (21) . The activity of plasminogen
activator inhibitor type I in arbitrary units (AU) was esti-
mated from the molar concentration of active plasminogen
activator inhibitor type I, assuming a specific molar activity
for plasminogen activator inhibitor type I of 4
.48 x 10
13
AU/mol, where I AU is the amount of active plasminogen
activator inhibitor type I that will inhibit I IU of t-PA
activity (17). The interassay standard deviation for the active
plasminogen activator inhibitor type I and t-PA/PAI-! com-
plex assays was 39 *- 9 pmol/liter
.
Epinephrine assay. Epinephrine was measured with a
single isotope radioenzymatic assay, as previously described
(22).
Statistical methods. Group data are presented as mean
values ± SEM, unless otherwise noted . Linear regression
and correlations were performed with standard methods .
The relation between plasma t-PA and plasma epineph-
rine concentration was modeled by the method of Laird and
Ware (23) after the variance components were estimated by
means of the EM algorithm (24). This method allows for
multiple measures in each individual subject
(that is, all data
points are not independent) and does not require completely
balanced data. Preliminary plots indicated that the concen-
tration of both total and active t-PA was linearly related to
the plasma concentration of epinephrine . In this study, we
were primarily interested in estimating the fixed or overall
response of t-PA to epinephrine levels . Therefore, the model
estimated the overall group response, the random or individ-
ual responses for each subject (which were assumed to
average to zero) and the errors within an individual response
(which were also assumed to average to zero) .
Results
Effect of epinephrine infusion . The average plasma epi-
nephrine concentration increased linearly with the rate of
epinephrine infusion (Fig. 1) . The average plasma epineph-
rine concentration increased 935%, from a baseline value of
69 :t 7 to 714 ± 73 ng/liter at an infusion rate of 50 ng/kg per
min . The correlation between epinephrine infusion rate and
average plasma epinephrine concentration was r = 0.977
(p = 0
.01).
Both total and active i-PA levels increased linearly with
the rate of epinephrine infusion (Fig . 1). Total t-PA in-
creased 46%, from a baseline value of 115 ± l I to 167 ±
12 pmollliter at the maximal epinephrine infusion rate . The
correlation between epinephrine infusion rate and average
total t-PA concentration was r = 0 .983 (p = 0.01). Active
EPINEPHRINE
INFUSION
(na/ka/ain)
Figure 1. Effect of epinephrine infusion on the plasma concentra-
tions of active and total tissue plasminogen activator (t-PA), active
plasminogen activator inhibitor type I (PAI-1), active t-PA/PAI-I
complex and epinephrine in 14 subjects . Error bars indicate mean
values ± SEM to = 14). L = liter
.
t-PA levels increased 233%, from a baseline of 16 .4 ±
1 .9 pmollliter to a maximum of 54 .6 ± 6.6 pmol/liter. The
correlation between epinephrine infusion rate and average
active t-PA concentration was r = 0.997 (p = 0 .002) . The
percent of t-PA in the active form increased from a baseline
value of 14 .5 ± 1 .8% to 35 .1 ± 5 .7% at an epinephrine
infusion rate of 50 ng/kg per min . The correlation between
epinephrine infusion rate and average percent active t-PA
was r = 0 .982 (p = 0 .009) .
There was no significant change in the concentration of
active plasminogen activator inhibitor type I (PAM) or
t-PA/PAI-I complex during the epinephrine infusion (Fig . I).
At baseline the average active plasminogen activator inhib-
Our type I concentration was 41 ± 11 versus 40 ± 10 pmol/liter
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Figuret. Effect of epinephrine infusion on heart rate, systolic blood
pressure and rate-pressure product in
14
subjects
. Error hogs
indicate mean values'_ SD . RPM = beats/min.
at the maximal epinephrine infusion rate . For t-PA/PAI-1
complex, the baseline concentration was 21 ± 5 versus 28
7 pmol/liter at the maximal epinephrine infusion rate.
A moderate degree of hemoconcentration occurred dew-
ing the epinephiirte fnfasion-
After correction for hemocort
,centration  active c-PA levels increased threefold during
epinephrine infusion, whereas active plasminogen activator
inhibitor type I and t-PA/PAI-I complex concentrations
demonstrated no significant change .
Infusion of epinephrine produced small but significant
increases in heart rate, systolic blood pressure and rate-
pressure product (Fig
. 2)
. Heart rate increased from 55 . I
beats/min at rest to 67 ± 3 beats/min at the maximal
epinephrine infusion rate (p = 0 .003, paired r test) and
systolic blood pressure increased from 124 ± 3 to 141
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3 mm Hg (p -
0.0002)
. Diastolic blood pressure decreased
slightly, from 73 ± I mm Hg at rest to 65 2
3 mm Hg at the
maximal epinephrine infusion rate (p = 0
.03)
.
Effect of graded exercise
. There was no significant differ-
ence in active I-PA, active plasminogen activator inhibitor
type i (P.tl-D. t-P4JBAI-l complex or total protein between
the baseline values before epinephrine infusion and the
baseline values before starting exercise
. Total t-PA was
slightly lower and plasma epinephrine slightly higher for the
exercise baseline value versus the epinephrine infusion
baseline value.
Not all subjects reached the same level of exercise before
exhaustion : :" of 14 exercised to a level of 167 W
. but only
3 to a level of 267 W
. Exercise results are expressed in two
ways
. Figure 3 shows the fibrinolytic results and Figure 4 the
hemodynamic results for each specific exercise level based
on an average of the values for all subjects who reached that
level of exercise . Table I compares fibrinelytic results for
rest versus maximal exercise-an average of the values at
exhaustion for all 14 subiects
. As noted, the maximal exer-
cise level reached varied among subjects .
Epinephrine levels in plasma increased exponentially
with the level of exercise (Fig. 3). Only small changes in
plasma epinephrine concentrations were seen at < 133 W, At
o 167 W, epinephrine levels increased rapidly
. Epinephrine
levels increased from a baseline value at rest of 105
-
14 ng/litcr to a level of 818 3 191 ng/titer at exhaustion
. The
average maximal level of epinephrine at exhaustion was not
significantly different from the average maximal level
reached during epinephrine infusion
.
Both total and active I-PA increased exponentially with
exercise in parallel with the epinephrine concentration (Fig
.
3). Total t-PA increased from a baseline value of 101 ±
10 pmol/liter to 194 s 22 pmollliter at exhaustion
. Active
I-FA levels increased coca
more dramatically, from a base-
line value of 16.7 m 2 pmollliter to l04 ± 26 pmoi/liter at
exhaustion. This resulted in the percent oft-PA in the active
form increasing from a baseline value of 19.4 ± 3 .3% to 42
.8
7.6% at exhaustion. In three subjects, the percent oft-PA
in the active form increased to between 90% and 100% of the
total t-PA level at the maximal exercise point .
Active
plasminogen
activator inhibitor type I levels dem-
onstrated only one
consistent
pattern during exercise,
namely, a small increase at the point of exhaustion
. This
increase in active plasminogen activator inhibitor type I is
not apparent in Figure 3, because the point of exhaustion
occurred at different exercise levels in different subjects, but
it can be seen in Table 1, which compares the rest level
versus the plasminogen activator inhibitor type I level at
exhaustion for all subjects. On average, total protein in-
creased 22% between baseline and exhaustion values, indi-
cating that a substantial degree of hemoconcentration oc-
curred (Table I) . After correction for hemoconcentration,
there was, on average, a 24% increase in active plasminogen
activator inhibitor type I at the point of exhaustion. The
1416
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Figure 3. Effect of graded supine exercise to exhaustion on the
plasma concentrations of active and total tissue plasminogen acti-
vator (t-PA), active plasminogen activator inhibitor type I (PAI-1),
active t-PAIPAI-I complex and epinephrine in 14 subjects . Each
exercise level was maintained for 3 min. The numbers in parentheses
(bottom graph) indicate the number of samples used in determining
the average for that point
. Error bars indicate mean values ± SEM
.
L = liter.
Concentration of t-PA/PAI-I complex did not significantly
change during exercise .
As expected, exercise produced substantial increases in
heart rate, systolic blood pressure and rate-pressure product
(Fig . 4)
. Heart rate increased from 62 ± 2 beats/min at
baseline study to 168 m 5 beatslmin at exhaustion, whereas
systolic blood pressure increased from 135 ± 3 to 216 ±
8 mm Hg. Diastolic blood pressure did not change signifi-
candy during exercise (86 ± 2 mm Hg at baseline study vs .
81 ± 4 mm iig at exhaustion) .
Plasma epinephrine versus t-PA level
. Overall, the con-
centration of active and total t-PA was linearly related to the
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Figure 4. Effect of graded supine exercise to exhaustion on heart
rate, systolic blood pressure and rate-pressure product in 14 sub-
jects. Each exercise level was maintained for 3 min . The number of
subjects at each level of exercise is shown in Figure 3
. Error bars
indicate mean values ± SD . BPM = beats/min
.
plasma epinephrine concentration during both epinephrine
infusion and exercise. Figure 5 shows the linear least-
squares fit between the plasma epinephrine concentration
and the active or total t-PA concentration for each subject
.
To simplify Figure 5, only the regression lines are shown for
each subject, not the individual data points . All points were
used in determining the regression lines . Using epinephrine
concentration as the independent variable and t-PA concen-
trations as the dependent variables, our analysis produced
an overall slope and intercept, as well as the individual
deviations from the overall estimates . We were not con-
cerned with the individual deviations (random effects), but
rather with the overall or fixed effects (shown as the dark
JACC Vol. 1 9. No. 7
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Table 1
. Fibrinolytic Variables Corrected for Hemoconcemration
During Epinephrine Infusion and Exercise in 14 Subjects
Active- Active' I-PAIPAI-I' Total
t-PA PAW
maple.
Protein
(pmoUliter)
	
(pmolditer) (pmoUliter) Igjliter.
-Individual fibrinolytic results were corrected for hcm0000cenlration
before averaging . based on measurements atonal protein during Rest 1 . fittest
I = sample after 30 min of supine rest just before the slant of epinephrine
infusion
; tRest 2 = sample after 30 min of supine rest just before beginning
exercise; Maximal epinephrine = sample after the infusion of the maximal
epinephrine concentration (50 ng/kg per min)
; Maximal exercise = samplejust
after maximal exercise at exhaustion . Note that m mat exercise levels
varied among subjects, depending an individual endurance
. PAM = plas-
minogen activator inhibitor type 1
: t-PA = tissue plasminogen activator .
Results am expressed as mean values x SEM .
lines in Fig. 5). During the infusion of epinephrine . the
overall response was :
[t-PA]ae,oe = 0
.062 ± 0.003[EPI] + 12.7 ± 0.7 pmolliter .
and
[t-PA]MN1 = 0 .076 ± 0.003[EPI] + 107
.9 ± 2.9 pmoUliter,
050-
Figures . Active and total tissue plas-
minogen activator (I-PA) concentra-
tions versus plasma epinephrine level
during epinephrine infusion (lee) and
exercise (right) in 14 subjects. Dotted
lines represent the linear least-
squares fit for each individual sub-
ject. Regression lima are shown for
each subject, not for individual data
points . For the epinephrine infusion
graphs (lee), the end points on the
dotted lines indicate the epinephrine
concentration at baseline and at the
end of the maximal epinephrine infu-
sion rate (50 ng/kg per min) . For the
exercise graphs (right), the end
points on the dotted Inns indicate the
epinephrine concentration at baseline
and at maximal exercise (point of
exhaustion)
. The sold lines in each
graph are the overall responses (see
text for a description of the analysis
used). Equations for the response
lines are given in the text . L = liter .
200-
150-
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where [t-PA] is the t-PA concentration in pmolliter and
[EPI] is the epinephrine concentration in ng/liter .
During exercise, the overall response was :
[t-PA],e y, e = 0.131 ± 0 .005[EPI] + 4.3 ± 0.1 pmoUliter,
and
(t-PA).., = 0
.147 ± 0.005[EPI] + 87 .5 x 2 .9 pmoUliter.
Although the t-PA concentration was linearly related to the
epinephrine concentration during both epinephrine infusion
and exercise, the rate of increase in t-PA versus epinephrine
(slope) was not the same . The ratio oft-PA to epinephrine
concentration increased approximately twice as fast during
exercise as during epinephrine infusion. For active t-PA
versus epinephrine
. the slope was 2.11 times higher during
exercise in comparison with epinephrine infusion (95% con-
fidence interval 1 .29 to 3.71) . For total t-PA versus epineph-
rine, the slope was 1 .95 times higher during exercise than
during epinephrine infusion (95% confidence interval 1 .38 to
2 .85) .
Discussion
Graded exercise to exhaustion produces an increase in
the circulating t-PA concentration that increases exponen-
tially with exercise intensity . The concentration of t-PA in
blood is regulated by three processes: secretion from the
PLASMA EPINEPM INE
109/rd.)
0
0 500 1000 1500 2000
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Rest It 16
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51 ! 6 36 2 8 25
.
5 87 n 5
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vascular endothelium, clearance by the liver and inhibition
by plasminogen activator inhibitor type I (PAI-I) .
Secretion oft-PA, Exercise and epinephrine infusion pro-
duced similar increases in plasma epinephrine levels
. Both
exercise and epinephrine infusion produced an increase in
t-PA that was directly proportional to the concentration of
epinephrine in blood . The release of t-PA typically occurs
within 2 to 3 min after infusion of epinephrine
(3) . During
exercise, the same rapid release pattern was seen ; t-PA
release did not occur until epinephrine levels began to
increase at the fourth or fifth exercise stage (133 to 167 W),
after which t-PA levels increased linearly with the concen-
tration of epinephrine (Fig
. 3 and 5) . We conclude that the
increased levels of epinephrine that occur during exercise
stimulate the release oft-PA . Furthermore, this observation
suggests that other situations that significantly iucrnse
circulating epinephrine levels would also be expected to
acrease t-FA activity (6,25) .
Although the time course and dose-response of t-PA
release were similar for epinephrine infusion and exercise,
the absolute rate of increase oft-PA versus epinephrine
concentration was twice as fast during exercise as with
infusion. Thus, approximately 50% of the increase in I-PA
during exercise could be directly related to stimulation by
epinephrine . The remaining 50% of the t-PA increase during
exercise must be due to other factors.
Mechanism oft-PA increase during exercise . Norepineph-
rine increases during exercise (4), but infusion of norepi-
nephrine has no effect on fibrinolytic activity (9). The
adrenergic specificity of I-PA release is still unclear . Al-
though epinephrine, isoproterenol and beta
2-adrenergic ag-
onists increase t-PA release, beta-adrenergic blockers such
as propranolol produce only small reductions in the fibrin-
olytic response to epinephrine (9,10) . Use of more specific
beta,- and beta,-blockers produces confusing results, at
times resulting in increased rather than decreased fibrin-
olytic activity after beta-adrenergic agonist infusion (9,26).
Furthermore, instead of reducing fibrinolytic activity, beta-
blockers given before exercise produce an increase in both
plasma epinephrine and fibrinolytic activity during exercise
(27,28) . Overall, beta-blockers do not substantially decrease
and may actually increase the release of t-PA by beta-
adrenergic agonists .
Vasupressin also increases during exercise(29)and infu-
sion of vasopressin and its analogue I-deamino-8-D-arginine
vasopressin stimulates fibrinolysis (30-32) . However, El-
sayed (29) showed that there was no correlation between
vasopressin levels during exercise and fibrinolytic activity .
Maximal t-PA release typically occurs 15 to 30 min after
administration of vasopressin or its analogue versus 2 to
3 min after epinephrine infusion (3,31 .32) . If vasopressin was
responsible for the increase in t-PA during exercise, we
would expect to find peak fibrinolytic activity occurring 15 to
30 min after the peak in vasopressin, which occurs at
exhaustion . Instead, fibrnotysis peaks at exhaustion then
decreases rapidly . Active t-PA has a half-life of 2 to 5 min
after exercise (1,8),
whereas total t-PA antigen has a half-life
of approximately 10 min after exercise (2) . Brommer et al .
(33) reported that infusion of vasopressin analogue had no
effect on t-PA levels in patients with congenital nephrogenic
diabetes insipidus compared with a threefold increase in
t-PA in normal control subjects after administration of
vasopressin analogue . The one patient with nephrogenic
diabetes insipidus who was able to exercise demonstrated no
response to vasopressin but had an increase in t-PA during
exercise, further demonstrating that factors other than vaso-
pressin are important in exercise-induced t-PA release.
It has been suggested that hypoxia, acidosis or metabo-
fires produced during exercise might stimulate r-PA release
.
Although Wheeler et al . (34) demonstrated that lactate
increases simultaneously with fibrinolytic activity during
exercise, at 8 min after exercise, lactate levels continued to
increase whereas fibrinolytic activity decreased rapidly,
indicating that lactate was not an important stimulator of
fibrinolysis . Stegnar et al
. (35) found that hynoxemia had no
effect on fibrinolysis, whereas Drygas (36) showed that a
prolonged submaximal exercise protocol could substantially
increase fibrinolytic activity without changing blood pH or
bicarbonate concentration .
Our results have shown that stimulation oft-PA secretion
due to increased levels of plasma epinephrine accounts for
approximately 50% of the increase in t-PA during exercise .
Although other as yet unknown factors may also increase
t-PA levels, it is unlikely that hypoxia-, acidosis- or exercise-
induced increases in norepinephrine, vasopressin or lactate
significantly stimulate t-PA release during exercise.
Hepatic clearance of t-PA- The second major process that
regulates t-PA levels is hepatic clearance, which at physio-
logic concentrations of t-PA is rapid, nonsaturable and
diffusion limited (37) . Infusion of epinephrine at the low
doses used in this study (10 to 50 n)kg per min) increases
hepatic blood flow and should therefore increase t-PA clear-
ance, resulting in a decrease in the circulating t-PA level
(38). Epinephrine infusion had only a minor effect on heart
rate and blood pressure . In contrast, exercise produced
major changes in heart rate and blood pressure . This level of
exercise decreases hepatic blood flow (39), which in turn
should reduce I-PA clearance by the liver, increasing the
circulating t-PA level . Reduced clearance of t-PA during
exercise may be an important mechanism that accounts in
part for the increase in t-PA not due to epinephrine stimu-
lation . The importance of liver clearance in regulating t-PA
levels is supported by studies (40) showing increased levels
of t-PA in patients with decreased clearance due to liver
cirrhosis .
Inhibition of t-PA by plasminogen activator inhibitor type
1 . The third mechanism for regulating active t-PA levels in
blood is inhibition by plasminogen activator inhibitor type I
.
This substance reacts with active t-PA to form t-PA/PAI-I
complex . Because complexed t-PA is cleared at a rate
similar to that for free t-PA (41), inhibition of active t-PA by
plasminogen activator inhibitor type I will not affect total
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t-PA levels in blood and affects only the active t-PA concen-
tration . The use of healthy active subjects (20) and perfor-
mance of
studied in the late morning and early afternoon
(42,43) resulted in low baseline levels of active plasminogen
activator inhibitor type I (average at rest 41 pmol/liter or 1 .8
arbitrary units/ml) . The low level of active plasminogen
activator inhibitor type I had little effect on active t-PA
levels, producing only a small amount of t-PA/PAI-I com
plex during exercise or epinephrine infusion (average at rest
21 pmolfliter or 1 .4 nglml of complexed t-PA) . Active plas-
minogen activator inhibitor type I and I-PA/PAl-I complex
levels showed little change during epinephrine infusion or
exercise, with the exception of a small increase in plasmi-
nogen activator inhibitor type I at the point of exhaustion .
Thus, alterations in plasminogen activator inhibitor type I
did not contribute to the changes noted in t-PA during
epinephrine infusion or exercise .
Study limitations . Our study has general limitations
.
First, only epinephrine was used as a stimulator of t-PA
release during exercise . Beta-adrenergic antagonists were
not used because they have been shown to accentuate rather
than block exercise-associated t-PA release (27,28) . Second.
we did not evaluate the effect ofchanges in hepatic clearance
during exercise, although such changes may play an impor-
tant role in regulating t-PA levels during exercise . Finally,
results in this study apply only to healthy subjects with low
plasminogen activator inhibitor type I levels
. Others
(7)
have
shown that active t-PA levels are reduced during exercise in
subjects with high plasminogen activator inhibitor type I
activity. Rydzewski et a1
.
(44) reported that patients with
exercise-induced ischemia had higher levels of plasminogen
activator inhibitor type I and were less able to produce
significant increases in t-PA activity and reductions in plas-
minogen activator inhibitor type I activity during exercise
than were healthy control subjects . Higher levels of
active
plasminogen activator inhibitor type I in their subjects
(averaging 200 vs. 33 pmolfliter before exercise in our study)
played an important role in neutralizing t-PA secreted during
exercise . Rydzewski et al . (44) found no correlation between
t-PA activity and epinephrine during exercise, but their
maximal exercise work loads averaged only
80 W
compared
with 200 W in our study . Epinephrine and t-PA levels did not
begin to increase significantly in our study until a supine
exercise level of 133 W was attained .
Conclusions . The increase in t-PA during exercise is due
to several factors. First, approximately 50% of the increase
is directly due to stimulation oft-PA release by an exercise-
induced increase in epinephrine levels . Other situations in
which plasma epinephrine increases would also be expected
to increase t-PA . Second, reduced clearance oft-PA during
exercise may also increase t-PA levels. Third, low plasmi-
nogen activator inhibitor type I levels appear to have little
effect on the concentration of active t-PA during exercise or
epinephrine infusion.
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